Individualized Targeted Therapy for Glioblastoma
نویسندگان
چکیده
منابع مشابه
Glioblastoma multiforme targeted therapy: The Chlorotoxin story.
Glioblastoma multiforme (GBM) is the most common malignant primary brain neoplasm having a mean survival of <24months. Scorpion toxins are considered promising cancer drug candidates, primarily due to the discovery of hlorotoxin, derived from the venom of the Israeli yellow scorpion. This intriguing short peptide of only 36 amino-acids length and tight configuration, possess the ability to bind...
متن کاملTargeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.
Antiangiogenic therapy can produce transient tumor regression in glioblastoma (GBM), but no prolongation in patient survival has been achieved. We have constructed a nanosystem targeted to tumor vasculature that incorporates three elements: (i) a tumor-homing peptide that specifically delivers its payload to the mitochondria of tumor endothelial cells and tumor cells, (ii) conjugation of this h...
متن کاملPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sens...
متن کاملMolecular imaging for visualization and quantification of individualized targeted cancer therapy
• Trastuzumab (Herceptin) directed against the HER-2 receptor and approved for treatment of metastatic breast cancer • Cetuximab (Erbitux) and panitumumab (Vectibix) directed against the epidermal growth factor receptor (EGFR) and approved for treatment of e.g. colorectal cancer • Bevacizumab (avastin) directed against the vascular endothelial growth factor (VEGF) and approved for treatment of ...
متن کاملIndividualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will discuss targeted therapies for colorectal cancers (CRC) based on EGFR signaling pathway and review publ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Cancer Journal
سال: 2012
ISSN: 1528-9117
DOI: 10.1097/ppo.0b013e318243f6c9